Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Molecular Expression and Diagnosis of Rheumatology
share announcement

Molecular Expression and Diagnosis of Rheumatology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (30 November 2024) | Viewed by 4256

Special Issue Editor

Dr. Shih-Yao Chen

E-Mail Website
Guest Editor
Chung Hwa College of Medical Technology Taiwan, Tainan, Taiwan
Interests: rheumatic diseases; arthritis; molecular expression; molecular diagnosis; molecular mechanism; molecular therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Rheumatology is a branch of medicine that focuses on the diagnosis and treatment of conditions and diseases that affect the musculoskeletal system, including joints, bones, muscles, and connective tissues. Molecular expression and diagnosis in rheumatology have advanced significantly in recent years, leading to the improved understanding and management of various rheumatic diseases. Some key aspects of molecular expression and diagnosis in rheumatology include biomarkers, autoantibodies, genetic testing, gene expression profiling, synovial fluid analysis, personalized medicine, and monitoring disease activity. It is important to note that while molecular diagnostics have greatly improved our understanding and management of rheumatic diseases, clinical evaluation and a holistic approach to patient care remain essential. Molecular markers are often used in conjunction with clinical assessments to provide a comprehensive view of a patient's condition. This Special Issue aims to compile studies related to new molecular diagnostics, mechanisms, and therapeutics in rheumatology. We welcome original research articles, short communications, and reviews and look forward to receiving your contributions.

Dr. Shih-Yao Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatology
  • rheumatic diseases
  • molecular diagnostics
  • molecular mechanisms
  • molecular therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1245 KiB  
Article
Obesity: Friend or Foe in Sjögren’s Syndrome Patients?
by Kincső Mezei, Laura Nagy, Viktória Orosz, Zsófia Aradi, Bernadett Bói and Antónia Szántó
Diagnostics 2024, 14(23), 2725; https://doi.org/10.3390/diagnostics14232725 - 3 Dec 2024
Viewed by 1172
Abstract
Background/Objectives: In Sjögren’s syndrome, exocrine glands are destructed in an autoimmune-mediated process. Obesity is known to influence a wide range of diseases. This study aimed to examine whether obesity has an impact on the disease course of our patients with Sjögren’s syndrome. Methods: [...] Read more.
Background/Objectives: In Sjögren’s syndrome, exocrine glands are destructed in an autoimmune-mediated process. Obesity is known to influence a wide range of diseases. This study aimed to examine whether obesity has an impact on the disease course of our patients with Sjögren’s syndrome. Methods: Out of the regularly followed-up patients, 125 were grouped based on their body mass index (BMI). Below a BMI of 25, they were listed as “non-obese” (n = 45), whereas above a BMI of 25, they were categorized as “obese” (n = 80). Demographic, laboratory, and immunological parameters; Sjögren’s syndrome disease activity index; certain extraglandular manifestations; and treatment modalities were compared using biostatistical methods. Results: Among the examined cardiovascular and cerebrovascular co-morbidities, type 2 diabetes and hypertension were significantly more frequent in the obese group. Considering the associated further autoimmune disorders and extraglandular manifestations, in our patients, there were no significant differences between the two groups. Among laboratory parameters, gamma glutamil transferase, alanine transaminase, hemoglobin, hematocrit, lymphocyte rate, triglyceride, and c3 and c4 complement levels were significantly higher in the obese group, while the proportion of rheumatoid factor positivity and the neutrophil granulocyte rate were significantly lower. Immunoglobulin G, A, and M levels did not differ significantly between the two subsets. Obese patients needed steroid therapy significantly less frequently; however, statin therapy was remarkably more frequent in that group. Furthermore, the European League Against Rheumatism (EULAR) Sjögren’s syndrome disease activity index (ESSDAI) was significantly lower in the group of overweight patients. Conclusions: Our results suggest that several immunological parameters of obese patients are more favorable compared to those with normal body weight. Behind that, we might suspect either the beneficial effect of statin therapy and/or the obesity paradox. Full article
(This article belongs to the Special Issue Molecular Expression and Diagnosis of Rheumatology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 760 KiB  
Review
Role of Myostatin in Rheumatoid Arthritis: A Review of the Clinical Impact
by Fabiola Gonzalez-Ponce, Melissa Ramirez-Villafaña, Eli Efrain Gomez-Ramirez, Ana Miriam Saldaña-Cruz, Sergio Gabriel Gallardo-Moya, Norma Alejandra Rodriguez-Jimenez, Heriberto Jacobo-Cuevas, Cesar Arturo Nava-Valdivia, Felipe Alexis Avalos-Salgado, Sylvia Totsuka-Sutto, Ernesto German Cardona-Muñoz and Edgar Ricardo Valdivia-Tangarife
Diagnostics 2024, 14(11), 1085; https://doi.org/10.3390/diagnostics14111085 - 23 May 2024
Cited by 1 | Viewed by 2368
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects synovial joints and that frequently involves extra-articular organs. A multiplicity of interleukins (IL) participates in the pathogenesis of RA, including IL-6, IL-1β, transforming growth factor-beta (TGF-β), and tumor necrosis factor (TNF)-α; immune cells [...] Read more.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects synovial joints and that frequently involves extra-articular organs. A multiplicity of interleukins (IL) participates in the pathogenesis of RA, including IL-6, IL-1β, transforming growth factor-beta (TGF-β), and tumor necrosis factor (TNF)-α; immune cells such as monocytes, T and B lymphocytes, and macrophages; and auto-antibodies, mainly rheumatoid factor and anti-citrullinated protein antibodies (ACPAs). Skeletal muscle is also involved in RA, with many patients developing muscle wasting and sarcopenia. Several mechanisms are involved in the myopenia observed in RA, and one of them includes the effects of some interleukins and myokines on myocytes. Myostatin is a myokine member of the TGF-β superfamily; the overproduction of myostatin acts as a negative regulator of growth and differentiates the muscle fibers, limiting their number and size. Recent studies have identified abnormalities in the serum myostatin levels of RA patients, and these have been found to be associated with muscle wasting and other manifestations of severe RA. This review analyzes recent information regarding the relationship between myostatin levels and clinical manifestations of RA and the relevance of myostatin as a therapeutic target for future research. Full article
(This article belongs to the Special Issue Molecular Expression and Diagnosis of Rheumatology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop